Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04729257 · ClinicalTrials.gov registry record · NA
Norms Expansion and Validation for IntelliSpace Cognition
A NA study of Cognitive Functioning of Healthy Individuals, sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization.
- Completed
- Registry status
- NA
- Development phase
- 508
- Enrollment target
- 1
- Study location
NCT04729257: Completed NA study of Cognitive Functioning of Healthy Individuals, sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization.
NCT04729257 is a NA study of Cognitive Functioning of Healthy Individuals that has completed, run by Philips Electronics Nederland B.V. acting through Philips CTO organization. The registered enrollment target is 508 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04729257, a NA study of Cognitive Functioning of Healthy Individuals, has completed, sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization.
- COMPLETED
- Registry status
- NA
- Development phase
- 508 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include ages 18-49 and 80+ and aims to validate two new digital tests.
Conditions Studied
Interventions
- DEVICE Philips IntelliSpace Cognition (ISC).
- DIAGNOSTIC_TEST Paper-Pencil Tests.
Study Locations (1)
Pennsylvania
- Research America Inc. - Newtown Square
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2021-07-02 |
| Phase | NA |
What the finished NCT04729257 record still lists
NCT04729257 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Cognitive Functioning of Healthy Individuals appearing as the primary indexed condition, and to 2 interventions - of which Philips IntelliSpace Cognition (ISC). is the first listed.
NCT04729257 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04729257 about?
NCT04729257 is a clinical study titled "Norms Expansion and Validation for IntelliSpace Cognition". This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include ages 18-49 and 80+ and aims to validate two new digital tests.
What is the current status of trial NCT04729257?
This trial is currently completed. It is a NA study. The enrollment target is 508 participants. The study started on 2021-03-08. Estimated completion is 2021-07-02.
What conditions does trial NCT04729257 study?
This clinical trial studies the following conditions: Cognitive Functioning of Healthy Individuals.
What interventions are being tested in trial NCT04729257?
The interventions under investigation include: Philips IntelliSpace Cognition (ISC). (DEVICE), Paper-Pencil Tests. (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04729257?
This trial is sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04729257 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04729257's enrollment target sits among peer trials
508 192nd of 2000 higher than 1,808 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI